Search

Author/Creator Del Tedesco, E.

1. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial. Issue 2 (27th April 2017)

Authors:
Roblin, X.; Boschetti, G.; Williet, N.; Nancey, S.; Marotte, H.; Berger, A.; Phelip, J. M.; Peyrin‐Biroulet, L.; Colombel, J. F.; Del Tedesco, E.; Paul, S.; Flourie, B.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 46:Issue 2(2017)
Page Start:
142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease. (20th April 2015)

Authors:
Roblin, X.; Marotte, H.; Leclerc, M.; Del Tedesco, E.; Phelip, J.M.; Peyrin-Biroulet, L.; Paul, S.
Journal:
Journal of Crohn's and colitis
Issue:
Volume 9:Number 7(2015:Jul.)
Page Start:
525
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor. Issue 8 (15th February 2018)

Authors:
Ben‐Horin, S.; Ungar, B.; Kopylov, U.; Lahat, A.; Yavzori, M.; Fudim, E.; Picard, O.; Peled, Y.; Eliakim, R.; Del Tedesco, E.; Paul, S.; Roblin, X.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 8(2018)
Page Start:
1117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗